Trial Profile
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Fevipiprant (Primary)
- Indications Acute asthma
- Focus Registrational; Therapeutic Use
- Acronyms LUSTER-2
- Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
- 24 Dec 2019 Topline combined analysis results from the Phase III LUSTER-1 and LUSTER-2 trials presented in a Novartis media release.
- 16 Dec 2019 According to a Novartis media release, the pivotal replicate LUSTER-1 and LUSTER-2 studies are part of the VIBRANT Phase III program, which also includes the SPIRIT safety study and the supplemental replicate ZEAL-1 and and ZEAL-2 studies.
- 16 Dec 2019 According to a Novartis media release, detailed efficacy and safety data from the LUSTER-1 and LUSTER-2 studies are being analyzed and will be submitted for presentation at an upcoming medical congress.